Cheilbio Co., Ltd. Overview
Cheilbio is a small, founder-built Korean manufacturer of veterinary medicines and feed additives, established in 1977 by a Seoul National University veterinary graduate and incorporated in 1989. Its portfolio spans functional feed additives, therapeutic drugs (antibiotics, antimicrobials, parasiticides, disinfectants), fermentation-based products (probiotics, enzymes, yeast culture) and diagnostic kits for cattle, pigs, poultry, aquaculture and pets. Revenue peaked near KRW 39.5bn in FY2014 and has since contracted to KRW 14.4bn in FY2025, with operating losses every year from FY2020 to FY2025. Since 2023 the company has been defined less by its products than by a family control dispute between the founder and his eldest daughter, criminal complaints (all later closed without indictment), two consecutive audit-opinion disclaimers, and a KRX delisting in February 2026 that a court has since ruled void at first instance. The business retains a cash-heavy, low-liability balance sheet, which is the core of its residual value case.
Company's own description
The FY2024 business report (filed with KIND on 7 April 2025) describes Cheilbio as a company established in January 1977 whose principal business is the manufacture of veterinary medicines and feed additives. The report classifies all activity under a single business segment, "animal drug manufacturing" (동물약품제조업). FnGuide's company summary, drawn from company filings, characterises the business as research, development, manufacturing and sale of fermentation-based animal drugs, alongside commercialisation of R&D results in product formulation and general feed additives.
Morningstar's profile lists the offering set as antibiotics, antimicrobials, lactobacillus (probiotic) products, enzyme preparations, parasiticides, antiseptics, organic trace minerals, vaccines, diagnostic kits (ELISA test kits, virus test kits and DNA kits) and feed additives, used for cattle, pigs, chickens, pets and other animals. Simply Wall St groups the range into nutrients/immune products, probiotics, functional products, antibiotics/antibacterials, anthelmintics/anticoccidials, kits, and disinfectants, serving poultry, swine, cattle, fisheries and pets.
Independent characterisation
Cheilbio is best understood as a sub-scale, domestically focused, mid-value-chain formulator and manufacturer. It converts purchased active ingredients and raw materials (the factory registry lists vitamins and antibiotics as principal raw materials) into finished veterinary drugs and feed additives at its Ansan plant, and it also manufactures fermentation-derived ingredients from in-house technology dating to 1990. It does not appear to own proprietary new chemical entities; the one product line described in detail in the FY2024 filing, a florfenicol injectable, competes head-to-head with a rival using the same originator-sourced raw material.
Business model and revenue model. Revenue is almost entirely product sales (manufactured products plus some traded merchandise). There is no disclosed service, subscription or licensing revenue. The FY2024 filing splits sales by channel as follows: feed-mill and special sales (50.10%), field sales to farms, veterinarians and distributors (34.25%), and exports (15.65%).
Value chain position. Upstream: purchases APIs (e.g., florfenicol of Novartis origin is implied by the filing's competitive note), vitamins and other inputs. Midstream: formulation, fermentation, and packaging at a KVGMP-type animal drug plant. Downstream: sells to (i) feed manufacturers who incorporate additives into compound feed, (ii) field channels (veterinary distributors and producers), and (iii) overseas distributors.
Customer types. Feed mills and integrators; livestock and poultry farms; veterinary distributors/clinics; aquaculture; companion-animal channels; export distributors.
End-markets. Korean livestock production (swine, poultry, cattle), aquaculture, and companion animals; selected export markets. A 2015 profile (Etoday) cited exports to 18 countries including China, Indonesia, Vietnam, Japan, Thailand and Taiwan; the current country list is not publicly disclosed.
Revenue mix by nature (FY2024, derived from KIND excerpt): manufactured products KRW 10,395.1M (74.7%); merchandise and other KRW 3,512.7M (25.3%, derived as the residual to total revenue).
Strategy
Stated corporate strategy. No investor-day material, medium-term plan or strategy statement was found in recent filings or press. The most recent articulated growth strategy dates from 2015 (CEO Sim Seung-gyu): leverage core fermentation and antibiotic-alternative technology, enter China through a local subsidiary, and reach KRW 100bn revenue by 2020. That target was missed by a wide margin (FY2021 revenue was about KRW 16.9bn).
Sustainability/ESG commitments, cost programmes and financial targets: not publicly disclosed. Management guidance: none published.
Products & Services
Cheilbio does not publish a product catalogue with specifications in sources accessible to this research. Pricing, launch years and specifications are not publicly disclosed for any product. The catalog below lists every product or category named in public sources.
Assessment. The portfolio is broad for a company of this size, covering nutrition, treatment, prevention and diagnosis, which suggests a distributor-friendly "full basket" model rather than a few differentiated products. Only one product (Flormax) is described in the FY2024 filing in any detail, and that description itself highlights direct competition with an equivalent product. Flagship-product data, version history and pricing are not publicly disclosed.
Product Portfolio
| Category / product | Description (as disclosed) | Target species / customer | Notes | Source |
|---|---|---|---|---|
Flormax (플로르맥스) injection | Florfenicol-based injectable specialising in treatment of pleuropneumonia; positioned as a respiratory-disease therapeutic | Swine (pleuropneumonia indication); field channel | Filing names Woojin (Woogene B&G) as main competitor, also using Novartis-origin raw material | KIND FY2024 report |
Saccharoculture (사카로컬춰) | Flagship fermentation product launched on the back of the company's 1990 domestic fermentation-raw-material technology | Livestock feed | Launch year not specified (post-1990) | Etoday (2015) |
Functional additives | Feed additives incl. nutrients/immune products, organic trace minerals, enzyme preparations | Feed mills; poultry, swine, cattle, aquaculture | Largest product line in FY2022 and FY2024 | KIND; Morningstar; Simply Wall St |
Therapeutics and other | Antibiotics, antimicrobials, anthelmintics, anticoccidials, disinfectants/antiseptics | Farms, vets, distributors | 30.8% of FY2024 revenue | KIND; Morningstar |
Fermentation products | Lactobacillus/probiotic products, enzyme preparations, yeast-culture type products | Feed and field | Described as antibiotic-alternative technology in 2015 profile | KIND; Etoday; aboda.kr summary |
Vaccines | Listed in Morningstar profile | Livestock | Not broken out in revenue table; may sit in merchandise/other | Morningstar |
Diagnostic kits | ELISA test kits, virus test kits, DNA kits | Vets, farms, labs | KRW 129.8M revenue FY2024 | KIND; Morningstar |
Health functional food / food additives | Listed as corporate purposes in articles of incorporation of some industry peers; not confirmed for Cheilbio | — | Not publicly disclosed for Cheilbio | — |
Financial Narrative
Basis and sources. FY2022-FY2024: KIND FY2024 business report excerpt (FY2023 restated). FY2025: JobKorea/KODATA record of FY2025 financial statements (business report filed 23 March 2026). FY2021: FnGuide (values reported in KRW 100M units, converted; therefore rounded to the nearest KRW 100M). EBITDA FY2021-FY2024: FnGuide. Blank cells = not publicly disclosed. The FY2025 audit opinion was not found; FY2023 and FY2024 statements received audit disclaimers, so all figures should be read with that qualification.
Income statement
FY2025 cost of sales and SG&A are derived (revenue minus gross profit; gross profit minus operating income). FY2024 EPS from FnGuide. Diluted EPS not publicly disclosed. No dividend declarations were found for FY2021-FY2025.
Below-the-line detail. FY2024: other gains KRW 470.6M, other losses KRW 308.6M, finance income KRW 508.9M, finance costs KRW 20.5M. FY2022: finance income KRW 1,106.4M, finance costs KRW 1,563.5M (the high finance cost likely reflects investment valuation losses; not specified). FY2025: non-operating income KRW 722.4M, non-operating expense KRW 278.8M.
Margins and growth (%)
All derived from 6.1. Revenue CAGR FY2021-FY2025: -3.8% (derived). FY2022-FY2025: -2.0% (derived). Long-run: from the FY2014 peak of KRW 39.53bn to FY2025's KRW 14.45bn, revenue has fallen 63% (derived), a CAGR of about -8.7% over 11 years.
Commentary. Three phases are visible. (1) FY2021-FY2022: revenue near KRW 15-17bn with thin gross margins (15.9% in FY2022) and operating losses of KRW 1.5-1.7bn, indicating that a low-margin, feed-mill-heavy mix could not cover a fixed SG&A base of about KRW 4bn. (2) FY2023: the dispute year. Revenue fell 36% (restated), mainly through the collapse of functional additives, while SG&A rose to KRW 4.35bn (likely including legal and governance costs; not itemised), producing the worst operating margin of the period (-20.5%). (3) FY2024-FY2025: partial recovery. Revenue rebounded to KRW 13.9-14.4bn, gross margin held at about 23%, and operating losses narrowed to KRW 1.06bn and then KRW 0.67bn. Net losses were much smaller than operating losses in FY2024-FY2025 because of non-operating and financial income (consistent with a large cash balance earning interest). The inflection is real but incomplete: the company remains loss-making at the operating line on an SG&A base it has not materially reduced.
Balance sheet
FY2024 figures from DigitalToday (Feb 2026), citing FY2024 statements.
Additional balance-sheet evidence. In the delisting-nullity case, counsel (Dongin LLC) told the court that Cheilbio held KRW 16.1bn of cash-equivalent assets within total assets of KRW 32.9bn (Hankyung, April 2026); the balance-sheet date was not specified in reporting but is most likely 31 December 2025. JobKorea/KODATA separately reports FY2025 total-asset growth of -5.53%, which would imply about KRW 33.3bn (derived) on the FY2024 base; the small gap to KRW 32.9bn is unexplained. Financial debt is not publicly disclosed; with total liabilities of only KRW 3.9bn at FY2024, any borrowings are necessarily small. Net debt is therefore negative (net cash), likely in the order of KRW 12-16bn, but the exact figure is not publicly disclosed. Capital reduction completed in October 2025 and conversion to no-par shares changed the composition of equity (share capital vs. reserves) but not total equity; details are not publicly disclosed.
Cash flow
Cash-flow statements were not accessible in sources reviewed. Known capital-return events: a KRW 2.5bn treasury trust in 2017; a treasury-share disposal decision on 12 June 2025 (amount not disclosed); and a buyback authorisation of up to 1,940 post-consolidation shares (KRW 2,022.8M ceiling) for 9-20 February 2026, with an acquisition-result report filed 25 February 2026 (amount executed not disclosed). Treasury holdings stood at 970 shares (5.00%) on 13 February 2026 (FnGuide).
Ratios
Sources: ROE FY2024 FnGuide; ROE and ROIC FY2025 JobKorea/KODATA; ROA FY2024, liabilities/equity and asset turnover derived from DigitalToday FY2024 figures; P/B from FnGuide (FY2024 reflects the suspended price of KRW 2,080). Current ratio, debt/equity on financial debt, net debt/EBITDA, interest coverage and cash conversion cycle: not publicly disclosed. Interest coverage is not meaningful given negative operating income (FY2024 finance cost was only KRW 20.5M).
Ratio commentary. Returns are marginally negative and improving (ROE -1.33% to -0.78%). The balance sheet is conservatively financed; the problem is not solvency but earnings power and asset productivity, with each KRW of assets generating only KRW 0.40 of sales in FY2024 because nearly half of assets are cash.
Interim results 2026
The Q1 2026 report (filed 15 May 2026) and H1 2026 report (filed 14 August 2026) exist (Saramin/NICE disclosure list), but their figures were not found in public sources reviewed: not publicly disclosed in accessible sources. For reference, FnGuide's last available interim data (nine months to September 2025) show revenue of KRW 10.6bn and a net loss of about KRW 0.2bn.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Product Lines
| Product line (KRW Mn) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Functional additives (KRW Mn) | 4,509.1 | 1,076.7 | 3,868.6 | — |
Therapeutics and other (KRW Mn) | 3,845.6 | 5,290.4 | 4,284.8 | — |
Fermentation products (KRW Mn) | 2,360.2 | 2,190.0 | 2,111.9 | — |
Diagnostic kits (KRW Mn) | 127.1 | 167.2 | 129.8 | — |
Manufactured products subtotal (KRW Mn, derived) | 10,842.0 | 8,724.3 | 10,395.1 | — |
Merchandise and other (KRW Mn, derived residual) | 4,506.6 | 1,098.5 | 3,512.7 | — |
Total revenue (KRW Mn) | 15,348.6 | 9,822.9 | 13,907.8 | 14,447.4 |
Product line share of total revenue (%)
| Product line share of total revenue (%) | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
Functional additives (%) | 29.4 | 11.0 | 27.8 |
Therapeutics and other (%) | 25.1 | 53.9 | 30.8 |
Fermentation products (%) | 15.4 | 22.3 | 15.2 |
Diagnostic kits (%) | 0.8 | 1.7 | 0.9 |
Merchandise and other (%) | 29.4 | 11.2 | 25.3 |
Product line YoY growth (%)
| Product line YoY growth (%) | FY2023 | FY2024 |
|---|---|---|
Functional additives (%) | -76.1 | 259.3 |
Therapeutics and other (%) | 37.6 | -19.0 |
Fermentation products (%) | -7.2 | -3.6 |
Diagnostic kits (%) | 31.5 | -22.4 |
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Mn) | 16,900 | 15,348.6 | 9,822.9 | 13,907.8 | 14,447.4 |
Revenue as originally reported (KRW Mn) | 16,900 | 15,348.6 | 12,110.8 | 13,907.8 | 14,447.4 |
Cost of sales (KRW Mn) | — | 12,904.0 | 7,493.8 | 10,689.1 | 11,091.5 |
Gross profit (KRW Mn) | — | 2,444.6 | 2,329.1 | 3,218.7 | 3,355.9 |
SG&A expenses (KRW Mn) | — | 3,930.1 | 4,347.0 | 4,280.4 | 4,021.2 |
Operating income (KRW Mn) | -1,700 | -1,485.5 | -2,017.9 | -1,061.7 | -665.3 |
EBITDA (KRW Mn) | -1,400 | -1,200 | -1,800 | -900 | — |
Pre-tax income (KRW Mn) | — | -1,755.6 | -1,464.1 | -411.4 | -221.7 |
Income tax expense (KRW Mn) | — | -47.8 | -18.3 | 5.2 | 9.4 |
Net income (KRW Mn) | -700 | -1,707.8 | -1,445.8 | -416.6 | -231.2 |
EPS basic (KRW, pre-consolidation) | — | — | — | -14 | — |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue growth YoY (%) | — | -9.2 | -36.0 | 41.6 | 3.9 |
Gross margin (%) | — | 15.9 | 23.7 | 23.1 | 23.2 |
Operating margin (%) | -10.1 | -9.7 | -20.5 | -7.6 | -4.6 |
EBITDA margin (%) | -8.3 | -7.8 | -18.3 | -6.5 | — |
Pre-tax margin (%) | — | -11.4 | -14.9 | -3.0 | -1.5 |
Net margin (%) | -4.1 | -11.1 | -14.7 | -3.0 | -1.6 |
Balance Sheet
| Metric | FY2024 |
|---|---|
Total assets (KRW Mn) | 35,200 |
Total liabilities (KRW Mn) | 3,900 |
Total equity (KRW Mn) | 31,300 |
Returns & Leverage Ratios (%) and Valuation Multiples (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE (%) | — | — | — | -1.33 | -0.78 |
ROA (%) | — | — | — | -1.18 | — |
ROIC (%) | — | — | — | — | -0.67 |
Total liabilities to equity (%) | — | — | — | 12.5 | — |
Asset turnover (x) | — | — | — | 0.40 | — |
Price to book high (x) | 3.12 | 2.36 | 1.84 | 1.62 | — |
Price to book low (x) | 2.19 | 0.91 | 0.89 | 1.62 | — |
Revenue by Region and Revenue by Region (%)
| Channel / region (KRW Mn) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Export (KRW Mn) | — | — | 2,177.0 | — |
Domestic feed and special sales (KRW Mn) | — | — | 6,967.3 | — |
Domestic field sales (KRW Mn) | — | — | 4,763.5 | — |
Total (KRW Mn) | 15,348.6 | 9,822.9 | 13,907.8 | 14,447.4 |
Channel share (%) | FY2024 | — | — | — |
Export (%) | 15.65 | — | — | — |
Domestic feed and special sales (%) | 50.10 | — | — | — |
Domestic field sales (%) | 34.25 | — | — | — |
Share Price and Market Valuation
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Share price high (KRW) | 4,371 | 3,205 | 2,395 | 2,080 | 2,080 |
Share price low (KRW) | 3,070 | 1,235 | 1,153 | 2,080 | 2,080 |
Market cap high (KRW Bn) | 127.2 | 93.4 | 69.8 | 60.6 | 60.6 |
Market cap low (KRW Bn) | 89.4 | 36.0 | 33.6 | 60.6 | 60.6 |
Valuation Multiples
| Multiple | Cheilbio | Basis |
|---|---|---|
Market cap (KRW Bn) | approx. 6.2 | KRW 320,000 x 19,419 shares |
P/B (x) | approx. 0.20 | vs FY2024 equity KRW 31.3bn |
EV/Sales (x) | negative | Cash KRW 16.1bn exceeds market cap |
Peer reference P/B | Woogene B&G about 0.8x (2025, per company statement to Edaily) | — |
Capital Markets
| Item | Status |
|---|---|
Analyst consensus | None; no coverage found |
Dividend history and policy | No dividends found for FY2021-FY2025; policy not disclosed |
Buyback authorisations | Up to 1,940 shares / KRW 2,022.8M (9-20 Feb 2026); 2017 KRW 2.5bn trust |
Credit ratings (Moody's/S&P/Fitch) | None; NICE offers a paid credit analysis report (rating not public) |
Debt maturity profile | Not publicly disclosed (liabilities KRW 3.9bn total at FY2024) |
Trading venue now | No organised exchange market since 23 Feb 2026; any OTC trading arrangements not confirmed |
Analyst Conclusions
Management guidance: none published. Consensus: none.
Bull case
-
Asset backing: at the last traded valuation of about KRW 6.2bn, the equity was priced at roughly 0.2x book and well below the KRW 16.1bn cash balance cited in court, so holders have a large margin of asset cover if value is ever realised or the listing is restored.
-
Legal momentum: all five criminal complaints have been closed without indictment and the company has won at first instance, the first time KRX has lost on the merits after winning at the injunction stage. A clean FY2025 or FY2026 audit opinion would remove the root cause of the disclaimers.
-
Operating improvement: operating losses have more than halved in two years (KRW -2.02bn to -0.67bn) with gross margin steady near 23%; modest revenue growth or SG&A trimming could return the business to breakeven within a market growing about 10% a year.
Bear case
-
Listing may not return: KRX has appealed, and two consecutive disclaimers are an independent formal delisting ground; tighter 2026-2027 KOSDAQ market-cap thresholds would also be hard to meet.
-
Structural decline: revenue is 63% below its FY2014 peak, the company lost money in each of the last six years, and its margins trail profitable peers by a wide gap, with no disclosed strategy or new products.
-
Governance overhang: the founder-family dispute is not formally settled, a new 11.6% holder has emerged, investor communication is minimal, and minority shareholders have no exchange liquidity.
Key catalysts and monitorables (next 12 months)
-
Appellate ruling in KRX's appeal against the 10 April 2026 judgement, and any Supreme Court petition.
-
FY2025 audit opinion (if not already clean) and the FY2026 audit opinion due in March 2027.
-
Q3 2026 report (mid-November 2026) and FY2026 results: whether operating income reaches breakeven.
-
Ownership changes: founder-side consolidation versus Lee Kyung-jae group intentions; any EGM requests.
-
Use of cash: buybacks, special distributions, investment or M&A.
-
Any re-listing application, or alternative liquidity arrangements for shareholders.
Analyst verdict. Cheilbio is no longer primarily an operating story; it is a legal and governance situation attached to a small, cash-rich, structurally challenged veterinary manufacturer. On fundamentals, the business has shrunk for a decade, from KRW 39.5bn of revenue in FY2014 to KRW 14.4bn in FY2025, and has not earned an operating profit since at least FY2020. Its gross margin of about 23% sits well below profitable listed peers such as Woogene B&G and Eagle Vet, and the disclosed portfolio suggests a commodity-leaning mix sold heavily through feed mills, where a supplier's reputational damage translates quickly into lost volume, as the 76% collapse in functional additives during FY2023 showed. Against this, the balance sheet is unusually conservative: liabilities of only KRW 3.9bn and roughly KRW 16bn of cash-equivalent assets, which means the company faces no near-term solvency risk and the narrowing of losses since FY2023 is credible.
The decisive variable is the appeal. The first-instance court accepted that the audit disclaimers were driven by allegations later dismissed and that the company's finances were sound, but the exchange retains a strong formal argument from the two consecutive disclaimers, and stricter listing-maintenance rules raise the bar for any return. Even a final win may restore rights more than liquidity.
For a research or counterparty user, Cheilbio should be treated as a going concern with low credit risk but high information risk: interim 2026 figures are not publicly accessible, audit quality has been compromised for three years, and governance remains concentrated in a divided founding family. Equity value, at about 0.2x book on the last traded price, is optionality on a legal outcome rather than on business performance. Confidence in this assessment is limited by the absence of accessible primary filings for 2026 and of any management communication.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Role | Tenure / dates | Background (as disclosed) |
|---|---|---|---|
Kang Dong-il (강동일) | Representative director (CEO) | CEO-change filing dated 31 Dec 2024; identified as CEO in Feb 2026 filings coverage | — |
Sim Kwang-kyung (심광경) | Founder; chairman; former CEO | Founder 1977; CEO until removal Apr 2023; reinstated Aug 2023 | SNU veterinary medicine graduate; age 84 in 2023 (Herald Economy); previously worked at a Korean company before founding |
Sim Ui-jeong (심의정) | Largest shareholder; former inside director | Chosen successor in 2016; inside director from Aug 2023 (described as "former" by Apr 2025) | Second daughter of founder |
Sim Yun-jeong (심윤정) | Former CEO; 5.23% shareholder | Inside director early 2023; CEO Apr-Aug 2023; removed by EGM | Eldest daughter; family-medicine physician |
Kang Ki-hoon (강기훈) | Former president | Party to 2023 complaints | Husband of Sim Yun-jeong (Dealsite) |
Sim Seung-gyu (심승규) | Former CEO | CEO around 2015; exited management and shares in 2016; holds 0.01% (2026) | Founder's son |
“—” = not publicly disclosed.
Major Shareholders
| Holder | Stake (FnGuide, as of 9-13 Feb 2026) | Stake (Saramin/NICE, later snapshot) | Notes |
|---|---|---|---|
Sim Ui-jeong | 14.04% | 19.32% | Largest shareholder |
Sim Kwang-kyung | 7.11% | 13.65% | Founder; filed a large-holding report on 24 Feb 2026 |
Lee Kyung-jae (incl. KJ Corporation) | not listed | 11.56% | Reported 8.81% on 10 Feb 2026 and 11.63% (2,258 shares) on 24 Feb 2026, accumulated during liquidation trading (DigitalToday) |
Kim Mun-ja | 5.29% | 5.28% | Founder's wife |
Sim Yun-jeong | 5.23% | not listed | Eldest daughter, adversary in dispute |
Treasury shares | 5.00% | — | 970 shares |
Jang Jae-wan | 0.02% | — | Related party |
Sim Seung-gyu | 0.01% | 0.01% | Founder's son |
Competitive Landscape
Peer Comparison FY2025
| Metric | Cheilbio | Woogene B&G | Eagle Vet |
|---|---|---|---|
Revenue (KRW Bn) | 14.45 | 30.20 | 43.32 |
Revenue growth YoY (%) | 3.9 | 14.5 | 3.9 |
Gross margin (%) | 23.2 | 29.9 | 34.1 |
Operating margin (%) | -4.6 | 7.3 | 9.8 |
Net margin (%) | -1.6 | 6.2 | 9.1 |
Employees | approx. 48-49 | approx. 97-103 | 108 |
Listing status | Delisted (litigation pending) | KOSDAQ | KOSDAQ |



